Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + fruquintinib + sintilimab
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination therapy consists of **liposomal irinotecan**, **fruquintinib**, and **sintilimab**. Liposomal irinotecan is a nanoparticle formulation of a topoisomerase I inhibitor designed to improve the pharmacokinetic profile and intratumoral concentration of the active metabolite SN-38. Fruquintinib is a highly selective and potent small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, thereby inhibiting tumor angiogenesis. Sintilimab is a recombinant humanized anti-programmed cell death protein 1 (PD-1) monoclonal antibody that restores T-cell mediated anti-tumor immune responses. The regimen is currently being evaluated as a second-line or later treatment for patients with advanced gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma, aiming to provide synergistic anti-tumor activity through combined cytotoxicity, anti-angiogenesis, and immune checkpoint inhibition.
- Other names
- liposomal irinotecan + fuquitinib + sindilizumabirinotecan liposome + fruquintinib + sintilimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on liposomal irinotecan + fruquintinib + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + fruquintinib + sintilimab.